Dexcom ONE+
Dexcom
What it is
A lower-cost, simplified real-time CGM built on the same sensor as the Dexcom G7 — same single-digit accuracy and 30-minute warm-up, but deliberately standalone: it does not drive insulin pumps or AID systems. Sold in the UK, Europe and New Zealand; no US offering is described in the sources read. An April 2026 correction covers ONE+ iOS app versions 1.5–1.6; affected users should follow the software update notice.
Editorial review: .
Most recent recorded citation date: 2026-04-08. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Accuracy: Shares the G7 sensor, whose pivotal study showed arm MARD 8.2%; a real-world ONE+ study in critically ill cardiac patients found MARD 11.6%.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 80 × 20 + 65 × 15 + 30 × 15 + 70 × 10 + 88 × 10 + 60 × 10 + 82 × 10 + 0 × 5 + 70 × 5 = 6375; divide by total weight 100. Unrounded weighted result: 63.75.
Shares the G7 sensor, whose pivotal study showed arm MARD 8.2%; a real-world ONE+ study in critically ill cardiac patients found MARD 11.6%.[1]
Interstitial lag like all current sensors; not a differentiator.
Deliberately standalone — does NOT integrate with insulin pumps or AID systems; no official DIY-loop support is described in the sources read. Phone/watch display only.[4]
10-day wear plus a 12-hour grace session; 15-day wear is signalled for the line (secondary-source expectation, unconfirmed).[5]
Customizable high/low alerts plus a low-glucose alert and a "delay 1st high" option; no G7-style predictive-alert suite is described in the ONE+ sources read.[7]
No ketone sensing is described in the sources read — glucose sensing only as described.
Sold in the UK; NHS-prescribable. No US offering is described in the sources read.[9]
The full picture
The Dexcom ONE+ is Dexcom's simplified, lower-cost real-time CGM, sold outside the US — in the UK, Europe, and the wider EMEA region. The cited launch announcement describes a February 2024 launch in Spain, Belgium, and Poland (with the Netherlands following the week after), rolling out across more EMEA markets through the year.3 It is the successor to the original Dexcom ONE, and the key upgrade is the sensor itself: ONE+ uses the same hardware platform as the Dexcom G7.4
How it works and how accurate it is. A small all-in-one sensor sits on your arm or abdomen, reads glucose in the fluid just under the skin, and sends a value to your phone every few minutes. Because it shares the G7 sensor, its registrational accuracy is the G7's: in the pivotal study, arm-worn sensors had a MARD (mean absolute relative difference — the average gap between sensor and lab blood glucose) of 8.2%, and abdomen 9.1% — single-digit, dose-from accuracy.1 A separate study of ONE+ specifically, in critically ill cardiac-ICU patients (a hard test case, with oxygen and blood-pressure drugs on board), found a MARD of 11.6%, with 99.6% of readings in the clinically safe zones — reassuring real-world performance even under stress.2 Like every current CGM, it reads interstitial fluid, so a physiological lag behind a fingerstick is expected, especially when glucose is moving fast.
Wear, warm-up, calibration. Each sensor lasts up to 10 days, with a 12-hour grace window to swap sensors.5 Warm-up is 30 minutes — far quicker than the 2-hour warm-up on the old ONE and G6.7 It is factory-calibrated, so no fingerstick calibrations are required, though optional manual calibration is available if you want it.6
Alerts. You get customizable high and low alerts, including a low-glucose alert you can set (for example, below 3.9 mmol/L for more than 30 minutes), plus a "delay 1st high" option to cut early-morning alert fatigue.75 No G7-style predictive alert suite (such as the "urgent low soon" early warning) is described in the ONE+ sources read.
What it works with — and what it doesn't. This is the deliberate trade-off. ONE+ is standalone: it displays on a compatible iOS or Android phone (and a paired watch), but it does not drive insulin pumps, does not power automated insulin delivery (AID) systems, and is not described in the sources read as a supported sensor for official DIY loops. If you want pump automation, Dexcom points you to the G7 instead.4 No ketone sensing is described in the ONE+ materials read — glucose sensing only as described.
Who it's for, and cost. It's indicated for ages 2 and older, including during pregnancy, for type 1, type 2, and gestational diabetes.5 It's sold in the UK, either per 10-day sensor or on a monthly/quarterly subscription, and it is prescribable on the NHS.9 No US offering is described in the sources read.
What's coming. A longer 15-day wear time has been signalled for the ONE+ line, which would lower the per-day cost further; treat this as expected rather than confirmed until Dexcom announces a regulatory clearance.8
Software correction. Medsafe lists an April 2026 correction for ONE+ iOS versions 1.5–1.6. After background operation, the app may display earlier readings before the current value and delay alerts. Affected users should update as directed by the manufacturer. This is a software correction, not a recall of all ONE+ sensors.10
Sources
- [1]Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes · Peer-reviewed study · 2022-02-21 — G7 pivotal (Garg et al., Diabetes Technol Ther 2022; PMID 35157505). Arm MARD 8.2%, abdomen 9.1%.
Garg SK, Kipnes M, Castorino K, et al. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther 24(6):373–380 (2022). PMID 35157505.
- [2]Accuracy of Dexcom One+ in Patients with Diabetes or Stress Hyperglycemia Hospitalized in Cardiac Intensive Care Unit · Peer-reviewed study · 2026-01-23 — Hohendorff et al., Diabetes Technol Ther 2026 (PMID 41574585). Direct ONE+ study; MARD 11.6%.
Hohendorff J, Zawislak B, Adamczyk-Hohendorff M, et al. Accuracy of Dexcom One+ in Patients with Diabetes or Stress Hyperglycemia Hospitalized in Cardiac Intensive Care Unit. Diabetes Technol Ther (2026). PMID 41574585.
- [3]Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People · Manufacturer · 2024-02-06 — EMEA launch (Spain, Belgium, Poland; Netherlands next week; further EMEA to follow).
Dexcom. Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People. Dexcom investor news (2024).
- [4]The New Dexcom ONE+ (product page) · Manufacturer — Confirms standalone use and that ONE+ shares the same hardware platform as G7; pumps require G7.
Dexcom. The New Dexcom ONE+ (product page, NZ): "Results obtained with Dexcom G7, which shares the same hardware platform as Dexcom ONE+." (2024).
Dexcom. The New Dexcom ONE+ (product page, NZ): directs users seeking insulin-pump (Tandem) integration to the Dexcom G7 — confirming ONE+ is standalone monitoring (2024).
- [5]Dexcom ONE+ FAQs · Manufacturer — 10-day wear + 12-hour grace; ages 2+ (pregnancy inclusion per the sibling NZ product page); iOS/Android app.
Dexcom. Dexcom ONE+ FAQs — 10-day wear + 12-hour grace; ages 2+ including pregnancy; iOS/Android app; settable low alert (2024).
- [6]The New Dexcom ONE+ (Estonia product page) · Manufacturer — Factory calibrated. Optional calibration for added flexibility.
Dexcom. The New Dexcom ONE+ (Estonia product page): "Factory calibrated. Optional calibration for added flexibility." (2024).
- [7]Introducing Dexcom ONE+ CGM · Manufacturer — 30-minute warm-up vs 2-hour on ONE/G6; alerts for high/low; arm/abdomen wear.
Dexcom. Introducing Dexcom ONE+ CGM — 30-minute warm-up vs 2-hour on ONE/G6; customizable high/low alerts; arm and abdomen wear (2024).
- [8]Dexcom ONE+ CGM — What You Need to Know · Science journalism — Reports 15-day weartime expected in future for the ONE+ line; secondary source.
Diabetech. Dexcom ONE+ CGM — What You Need to Know — reports that a 15-day weartime is expected in the future for the Dexcom ONE+ (secondary source; not yet a confirmed regulatory clearance).
- [9]Dexcom ONE+ Sensor (UK shop) · Manufacturer — UK retail pricing, sold per sensor or on monthly/quarterly subscription.
Dexcom. Dexcom ONE+ Sensor (UK shop): single 10-day sensor, or monthly/quarterly subscription (2024).
- [10]Medsafe: Dexcom G7 and ONE+ iOS software correction · Regulatory decision · 2026-04-08